Arbelli

Arbele is a clinical-stage biotechnology company specializing in the development of innovative immunotherapies for gastrointestinal (GI) cancers. The company leverages its proprietary platforms to target Cadherin-17 (CDH17), a biomarker that is highly specific to the GI tract and frequently overexpressed in tumors such as gastric, colorectal, and pancreatic cancers. Arbele's pipeline includes a diverse range of modalities, including bispecific T-cell engagers (TCEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) cell therapies. Its lead program, ARB202, is a first-in-class bispecific antibody targeting CDH17 and CD3, currently in Phase 1 clinical trials. The company aims to address significant unmet needs in GI oncology by providing more precise and effective treatment options.